UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | J | K | L | M | N | O | P | R | S | T | U | V | W | Y
Number of items: 112.

A

Acosta, D; Patkar, V; Keshtgar, M; Fox, J; (2010) Challenges in Delivering Decision Support Systems: The MATE Experience. In: Riano, D and TenTeije, A and Miksch, S and Peleg, M, (eds.) KNOWLEDGE REPRESENTATION FOR HEALTH-CARE: DATA, PROCESSES AND GUIDELINES. (pp. 124 - 140). SPRINGER-VERLAG BERLIN

Antonow, D; Kaliszczak, M; Kang, GD; Coffils, M; Tiberghien, AC; Cooper, N; ... Thurston, DE; + view all (2010) Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents. J MED CHEM , 53 (7) 2927 - 2941. 10.1021/jm901722v.

Arkenau, H; (2010) Principles of Anticancer Drug Development. In: Garrett-Mayer, E, (ed.) Principles of Anticancer Drug Development. (? - ?). Springer Verlag

B

Berenjeno, IM; Vanhaesebroeck, B; (2010) PI3K Regulatory Subunits Lose Control in Cancer (DOI:10.1016/j.ccr.2009.11.017). Cancer Cell , 17 (2) 213 - 213. 10.1016/j.ccr.2010.01.010.

Bilanges, B; Vanhaesebroeck, B; (2010) A new tool to dissect the function of p70 S6 kinase. Biochem J , 431 (2) e1 - e3. 10.1042/BJ20101445.

Bockenhauer, D; Reichold, M; Zdebik, A; Lieberer, E; Schmidt, K; Rapedius, M; ... Kleta, R; + view all (2010) Altered Renal Tubular Ultrastructure and Electrophysiology Caused by KCNJ10 Mutations in EAST Syndrome. PEDIATR NEPHROL , 25 (9) 1980 - 1980.

Boss, DS; Schwartz, GK; Middleton, MR; Amakye, DD; Swaisland, H; Midgley, RS; ... Shapiro, GI; + view all (2010) Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. ANN ONCOL , 21 (4) 884 - 894. 10.1093/annonc/mdp377.

Brada, M; Stenning, S; Gabe, R; Thompson, LC; Levy, D; Rampling, R; ... Lee, SM; + view all (2010) Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. JOURNAL OF CLINICAL ONCOLOGY , 28 (30) 4601 - 4608. 10.1200/JCO.2009.27.1932.

Bridgewater, J; Wasan, H; Valle, J; (2010) Cisplatin plus Gemcitabine for Biliary Tract Cancer REPLY. NEW ENGLAND JOURNAL OF MEDICINE , 363 (2) 192 - 193.

Brucoli, F; Hawkins, RM; Wells, G; Jenkins, TC; Ellis, T; Kotecha, M; ... Thurston, DE; + view all (2010) A potent PBD-heterocyclic polyamide conjugate targeting an ICB2 transcription factor binding site. In: EJC SUPPLEMENTS. (pp. 168 - 168). PERGAMON-ELSEVIER SCIENCE LTD

Brunetto, AT; Ang, JE; Olmos, D; Tan, D; Barriuso, J; Arkenau, HT; ... Kaye, S; + view all (2010) A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur J Cancer , 46 (15) 2739 - 2745. 10.1016/j.ejca.2010.06.123.

Brunetto, AT; De Bono, JS; Kristeleit, RS; (2010) Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncology , 6 (8) 1339 - 1352. 10.2217/fon.10.92.

C

Cain, RJ; Vanhaesebroeck, B; Ridley, AJ; (2010) The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1. J Cell Biol , 188 (6) 863 - 876. 10.1083/jcb.200907135.

Calvert, AH; (2010) PARP INHIBITORS IN CLINICAL DEVELOPMENT - AN OVERVIEW. In: ANNALS OF ONCOLOGY. (pp. 17 - 17). OXFORD UNIV PRESS

Chavda, S; Babu, B; Yanow, SK; Jardim, A; Spithill, TW; Kiakos, K; ... Lee, M; + view all (2010) A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: Synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation. BIOORGAN MED CHEM , 18 (14) 5016 - 5024. 10.1016/j.bmc.2010.05.078.

Chavda, S; Mulder, K; Brown, T; Mackay, H; Babu, B; Westrate, L; ... Lee, M; + view all (2010) DNA Recognition: Design, Synthesis and Biophysical Characteristics of Pyrrole(H) Based Polyamides. MED CHEM , 6 (3) 150 - 158.

Cox, ST; Stephens, HA; Fernando, R; Harber, M; Howie, A; Powis, S; ... Little, AM; + view all (2010) MICA allele mismatching, MICA antibodies and rejection in renal transplantation. In: TISSUE ANTIGENS. (pp. 481 - 481). WILEY-BLACKWELL PUBLISHING, INC

D

Dick, J; Begent, RH; Meyer, T; (2010) Sarcoidosis and testicular cancer: A case series and literature review. UROL ONCOL-SEMIN ORI , 28 (4) 350 - 354. 10.1016/j.urolonc.2008.09.029.

F

Fenton, TR; Gwalter, J; Cramer, R; Gout, IT; (2010) S6K1 is acetylated at lysine 516 in response to growth factor stimulation. BIOCHEM BIOPH RES CO , 398 (3) 400 - 405. 10.1016/j.bbrc.2010.06.081.

Fenton, TR; Gwalter, J; Ericsson, J; Gout, IT; (2010) Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo. INT J BIOCHEM CELL B , 42 (2) 359 - 366. 10.1016/j.biocel.2009.11.022.

Fern, LA; Whelan, JS; (2010) Recruitment of adolescents and young adults to cancer clinical trials--international comparisons, barriers, and implications. Semin Oncol , 37 (2) e1 - e8. 10.1053/j.seminoncol.2010.04.002.

Fischer, U; Leidinger, P; Keller, A; Folarin, A; Keller, R; Graf, N; ... Meese, E; + view all (2010) Amplicons on chromosome 12q13-21 in glioblastoma recurrences. INT J CANCER , 126 (11) 2594 - 2602. 10.1002/ijc.24971.

Fish, R; Pinney, J; Jain, P; Addison, C; Jones, C; Jayawardene, S; ... Hutchison, CA; + view all (2010) The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies. CLIN J AM SOC NEPHRO , 5 (11) 1977 - 1980.

Fogo, AB; Bostad, L; Svarstad, E; Cook, WJ; Moll, S; Barbey, F; ... ISGFN,; + view all (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). NEPHROLOGY DIALYSIS TRANSPLANTATION , 25 (7) 2168 - 2177. 10.1093/ndt/gfp528.

Folarin, AA; Konerding, MA; Timonen, J; Nagl, S; Pedley, RB; (2010) Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. MICROVASC RES , 80 (1) 89 - 98. 10.1016/j.mvr.2010.03.007.

Ford, H; Hochhauser, D; Paterson, A; Lovat, L; Jobanputra, M; Fitzgerald, RC; (2010) Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer. JOURNAL OF CLINICAL ONCOLOGY , 28 (15)

Forster, M; Enting, D; Nicholson, AG; O'Brien, M; Popat, S; (2010) The combination of Young's syndrome and small cell lung cancer-A spiky connection? Lung Cancer , 67 (3) 372 - 375. 10.1016/j.lungcan.2009.10.011.

Forster, MD; Saijo, N; Seymour, L; Calvert, H; (2010) Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan. CLIN CANCER RES , 16 (6) 1737 - 1744. 10.1158/1078-0432.CCR-09-2228.

Foukas, LC; Berenjeno, IM; Gray, A; Khwaja, A; Vanhaesebroeck, B; (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. P NATL ACAD SCI USA , 107 (25) 11381 - 11386. 10.1073/pnas.0906461107.

Fox, J; Glasspool, D; Patkar, V; Austin, M; Black, L; South, M; ... Vincent, C; + view all (2010) Delivering clinical decision support services: There is nothing as practical as a good theory. J BIOMED INFORM , 43 (5) 831 - 843. 10.1016/j.jbi.2010.06.002.

Franks, A; Tronrud, C; Kiakos, K; Kluza, J; Munde, M; Brown, T; ... Lee, M; + view all (2010) Targeting the ICB2 site of the topoisomerase II alpha promoter with a formamido-pyrrole-imidazole-pyrrole H-pin polyamide. BIOORGAN MED CHEM , 18 (15) 5553 - 5561. 10.1016/j.bmc.2010.06.041.

G

Germani, G; Pleguezuelo, M; Gurusamy, K; Meyer, T; Isgro, G; Burroughs, AK; (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. J HEPATOL , 52 (3) 380 - 388.

Giampieri, S; Pinner, S; Sahai, E; (2010) Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res , 70 (9) 3435 - 3439. 10.1158/0008-5472.CAN-10-0466.

Gillmore, R; Laurence, V; Raouf, S; Tobias, J; Blackman, G; Meyer, T; ... Bridgewater, J; + view all (2010) Chemoradiotherapy with or without Induction Chemotherapy for Locally Advanced Pancreatic Cancer: a UK Multi-institutional Experience. CLIN ONCOL-UK , 22 (7) 564 - 569. 10.1016/j.clon.2010.05.007.

H

Hartley, JA; Hamaguchi, A; Coffils, M; Martin, CRH; Suggitt, M; Chen, ZZ; ... Howard, PW; + view all (2010) SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity. CANCER RES , 70 (17) 6849 - 6858. 10.1158/0008-5472.CAN-10-0790.

Holme, H; Nanduri, V; (2010) Paediatric presentation of familial cerebral cavernoma. Pediatr Blood Cancer , 54 (3) 468 - 469. 10.1002/pbc.22288.

Howie, AJ; Owen-Casey, MP; (2010) Discrepancies between descriptions and illustrations of colours in Congo red-stained amyloid, and explanation of discrepant colours. Amyloid , 17 (3-4) 109 - 117. 10.3109/13506129.2010.527448.

Hua, J; Spee, C; Kase, S; Rennel, ES; Magnussen, AL; Qiu, Y; ... Hinton, DR; + view all (2010) Recombinant Human VEGF(165)b Inhibits Experimental Choroidal Neovascularization. INVEST OPHTH VIS SCI , 51 (8) 4282 - 4288. 10.1167/iovs.09-4360.

J

jones, A; lechner, M; fourkala, E; Kristeleit, R; Widschwendter, M; (2010) Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics , 2 (1) 9 - 38.

Juul, N; Szallasi, Z; Eklund, AC; Li, Q; Burrell, RA; Gerlinger, M; ... Swanton, C; + view all (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol , 11 (4) 358 - 365. 10.1016/S1470-2045(10)70018-8.

K

Khan, M; Tsigani, T; Rashid, M; Luong, TV; Caplin, M; Meyer, T; (2010) EpCam Expression and Detection of Circulating Tumor Cells in Neuroendocrine Tumors. In: NEUROENDOCRINOLOGY. (pp. 38 - 38). KARGER

Kiakos, K; Hartley, JM; Hartley, JA; (2010) Measurement of DNA interstrand crosslinking in naked DNA using gel-based methods. Methods Mol Biol , 613 283 - 302. 10.1007/978-1-60327-418-0_18.

Kuehn, HS; Rådinger, M; Brown, JM; Ali, K; Vanhaesebroeck, B; Beaven, MA; ... Gilfillan, AM; + view all (2010) Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci , 123 (Pt 15) 2576 - 2585. 10.1242/jcs.071043.

L

Lafont, E; Milhas, D; Carpentier, S; Garcia, V; Jin, ZX; Umehara, H; ... Ségui, B; + view all (2010) Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death Differ , 17 (4) 642 - 654. 10.1038/cdd.2009.130.

Lafont, E; Milhas, D; Teissié, J; Therville, N; Andrieu-Abadie, N; Levade, T; ... Ségui, B; + view all (2010) Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk. PLoS One , 5 (10) , Article e13638. 10.1371/journal.pone.0013638. Green and gold open access
file

Ledermann, JA; Gabra, H; Jayson, GC; Spanswick, VJ; Rustin, GJS; Jitlal, M; ... Hartley, JA; + view all (2010) Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer. CLIN CANCER RES , 16 (19) 4899 - 4905. 10.1158/1078-0432.CCR-10-0832.

Ledermann, JA; Kristeleit, RS; (2010) Optimal treatment for relapsing ovarian cancer. ANN ONCOL , 21 218 - 222. 10.1093/annonc/mdq377.

Ledermann, JA; Raja, FA; (2010) Targeted trials in ovarian cancer. GYNECOL ONCOL , 119 (1) 151 - 156. 10.1016/j.ygyno.2010.05.008.

Lee, SM; (2010) First-line maintenance (1LM) treatment: a new strategy to treat advanced NSCLC. Oncology News , 4 (6) 88 - 91.

Lee, SM; Baas, P; Wakelee, H; (2010) Anti-angiogenesis drugs in lung cancer. Respirology , 15 (3) 387 - 392. 10.1111/j.1440-1843.2010.01715.x.

Lee, SM; Bass, P; Wakelee, H; (2010) Anti-angiogenesis drugs in lung cancer. Respirology 387 - 392.

Liccardi, G; Hartley, JA; Hochhauser, D; (2010) EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. In: EJC SUPPLEMENTS. (pp. 166 - 166). PERGAMON-ELSEVIER SCIENCE LTD

Low, PC; Misaki, R; Schroder, K; Stanley, AC; Sweet, MJ; Teasdale, RD; ... Stow, JL; + view all (2010) Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion. J Cell Biol , 190 (6) 1053 - 1065. 10.1083/jcb.201001028.

M

Magnussen, AL; Rennel, ES; Hua, J; Bevan, HS; Long, NB; Lehrling, C; ... Churchill, AJ; + view all (2010) VEGF-A(165)b Is Cytoprotective and Antiangiogenic in the Retina. INVEST OPHTH VIS SCI , 51 (8) 4273 - 4281. 10.1167/iovs.09-4296.

Mahendran, AO; Papakrivopolou, J; Haroon, S; Dupont, PJ; Howie, AJ; Veitch, PS; (2010) The Troubled Transplant: Can Early Surveillance Biopsy Predict the "At Risk Graft?". In: AMERICAN JOURNAL OF TRANSPLANTATION. (pp. 437 - 438).

Martin, V; Guillermet-Guibert, J; Chicanne, G; Cabou, C; Jandrot-Perrus, M; Plantavid, M; ... Gratacap, MP; + view all (2010) Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood , 115 (10) 2008 - 2013. 10.1182/blood-2009-04-217224.

Mattila, K; Hyvaluoma, J; Folarin, AA; Rossi, T; (2010) A boundary condition for arbitrary shaped inlets in lattice-Boltzmann simulations. INT J NUMER METH FL , 63 (5) 638 - 650. 10.1002/fld.2101.

Mellinas-Gomez, M; Spanswick, VJ; Stell, A; Hartley, JA; Thurston, DE; Baines, S; (2010) Investigation of the effect of the sequence-selective DNA cross-linking agent SJG-136 on canine tumour cells in vitro. In: EJC SUPPLEMENTS. (pp. 91 - 91). PERGAMON-ELSEVIER SCIENCE LTD

Meyer, T; (2010) Vascular disruptive agents for the treatment of cancer.

Meyer, T; Caplin, ME; Palmer, DH; Valle, JW; Larvin, M; Waters, JS; ... Kato, H; + view all (2010) A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. EUR J CANCER , 46 (3) 526 - 533. 10.1016/j.ejca.2009.11.004.

Meyer, T; Roughton, M; Yu, D; Davies, N; Williams, E; Pereira, S; ... Burroughs, AK; + view all (2010) A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). In: Journal of Clinical Oncology. (pp. 4025 - ?).

Meyer, T; Roughton, M; Yu, D; Davies, N; Williams, E; Pereira, SP; ... Burroughs, AK; + view all (2010) A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). JOURNAL OF CLINICAL ONCOLOGY , 28 (15)

Middleton, MR; Knox, R; Cattell, E; Oppermann, U; Midgley, R; Ali, R; ... Kerr, DJ; + view all (2010) Quinone Oxidoreductase-2-Mediated Prodrug Cancer Therapy. SCI TRANSL MED , 2 (40) , Article 40ra50. 10.1126/scitranslmed.3000615.

Molife, LR; Fong, PC; Paccagnella, L; Reid, AH; Shaw, HM; Vidal, L; ... de Bono, JS; + view all (2010) The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer , 103 (3) 332 - 339. 10.1038/sj.bjc.6605767.

Munding, J; Baraniskin, A; Meier, D; Porschen, R; Arkenau, H; Graeven, U; ... Reinacher-Schick, A; + view all (2010) Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy - a study of the AIO colorectal cancer group (AIO). ONKOLOGIE , 33 71 - 72.

N

Nutt, JE; Razak, ARA; O'Toole, K; Black, F; Quinn, AE; Calvert, AH; ... Lunec, J; + view all (2010) The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. BRIT J CANCER , 102 (3) 553 - 560. 10.1038/sj.bjc.6605501.

O

Oliveira, JP; Fogo, AB; Bostad, L; Svarstad, E; Cook, WJ; Moll, S; ... ISGFN,; + view all (2010) SCORING SYSTEM FOR RENAL PATHOLOGY IN FABRY DISEASE: REPORT OF THE INTERNATIONAL STUDY GROUP OF FABRY NEPHROPATHY (ISGFN). In: CLINICAL THERAPEUTICS. (pp. S105 - S105).

Orikawa, Y; Kato, H; Seto, K; Kobayashi, N; Yoshinaga, K; Hamano, H; ... Takei, M; + view all (2010) Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 beta production in a cancer-induced pain model in mice. MOL PAIN , 6 , Article 72. 10.1186/1744-8069-6-72. Gold open access

P

Patkar, V; Acosta, D; Fox, J; Jones, A; Davidson, T; Keshtgar, M; (2010) A novel support tool for Breast Multidisciplinary Meetings: an advanced evidence based computer decision support technology. In: EJC SUPPLEMENTS. (pp. 211 - 211). PERGAMON-ELSEVIER SCIENCE LTD

Patkar, V; Acosta, D; Naughton, P; Fox, J; Jones, A; Keshtgar, M; (2010) An advanced computerised decision support system for breast cancer multidisciplinary meetings: results of an audit study. In: BRITISH JOURNAL OF SURGERY. (pp. 42 - 42). JOHN WILEY & SONS LTD

Patterson, DM; Lee, SM; (2010) Glucarpidase following high-dose methotrexate: update on development. Expert Opin Biol Ther , 10 (1) 105 - 111. 10.1517/14712590903468677.

Pearce, S; Gibson, F; Fern, L; O'Hare, C; Taylor, R; Whelan, JS; (2010) The 'Essence of care study' for teenagers and young adults with cancer: a national longitudinal study to assess the benefits of specialist care. Phase I: feasibility and scoping study.

PEDLEY, R; Sharma, SK; (2010) Xenograft Mouse Models for Tumour Targeting. In: Kontermann, R, (ed.) Antibody Engineering. (? - ?). Springer Verlag

Pedley, RB; tozer, G; (2010) Vascular Disruptive Agents for the Treatment of Cancer. In: Meyer, T, (ed.) Vascular Disruptive Agents for the Treatment of Cancer. (49 - 75). Springer Verlag

R

Radhakrishnan, S; Miranda, E; Ekblad, M; Holford, A; Pizarro, MT; Lemoine, NR; Halldén, G; (2010) Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor Xenografts. Human Gene Therapy , 21 (10) 1311 - 1325. 10.1089/hum.2010.019.

Ramadani, F; Bolland, DJ; Garcon, F; Emery, JL; Vanhaesebroeck, B; Corcoran, AE; Okkenhaug, K; (2010) The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal , 3 (134) ra60 - ?. 10.1126/scisignal.2001104.

Razak, AA; Nutt, J; O'Toole, K; Black, F; Cole, M; Plummer, R; ... Calvert, H; + view all (2010) Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy. In: EJC SUPPLEMENTS. (pp. 173 - 173). PERGAMON-ELSEVIER SCIENCE LTD

Reichold, M; Zdebik, AA; Lieberer, E; Rapedius, M; Schmidt, K; Bandulik, S; ... Warth, R; + view all (2010) KCNJ10 gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. P NATL ACAD SCI USA , 107 (32) 14490 - 14495. 10.1073/pnas.1003072107.

Ringland, CL; Arkenau, HT; O'Connell, DL; Ward, RL; (2010) Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. Ann Oncol , 21 (1) 92 - 97. 10.1093/annonc/mdp288.

Rodriguez-Acebes, S; Proctor, I; Loddo, M; Wollenschlaeger, A; Rashid, M; Falzon, M; ... Williams, GH; + view all (2010) Targeting DNA Replication before it Starts Cdc7 as a Therapeutic Target in p53-Mutant Breast Cancers. AM J PATHOL , 177 (4) 2034 - 2045. 10.2353/ajpath.2010.100421.

S

Scatchard, K; Lee, SM; (2010) Neurotoxicity of chemotherapy. In: Neuro-Oncology: Blue Books of Neurology Series. (352 - 371). Elsevier

Shamash, J; Stebbing, J; Sweeney, C; Sonpavde, G; Harland, S; Dawkins, G; ... Powles, T; + view all (2010) A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer , 116 (15) 3595 - 3602. 10.1002/cncr.25194.

Silini, A; Chiorino, G; Ghilardi, C; Dahse, R; Pedley, RB; Giavazzi, R; Bani, MR; (2010) Differences in the stroma of human ovarian carcinoma xenografts endowed with different angiogenic phenotypes. In: EJC SUPPLEMENTS. (pp. 94 - 95). PERGAMON-ELSEVIER SCIENCE LTD

Spanswick, VJ; Hartley, JM; Hartley, JA; (2010) Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay. Methods Mol Biol , 613 267 - 282. 10.1007/978-1-60327-418-0_17.

Srirajaskanthan, R; Caplin, ME; Waugh, MG; Watkins, J; Meyer, T; Hsuan, JJ; Beaumont, NJ; (2010) Identification of Mac-2-binding Protein as a Putative Marker of Neuroendocrine Tumors from the Analysis of Cell Line Secretomes. MOL CELL PROTEOMICS , 9 (4) 656 - 666. 10.1074/mcp.M900401-MCP200.

Strauss, SJ; Ng, T; Mendoza-Naranjo, A; Whelan, J; Sorensen, PHB; (2010) Understanding Micrometastatic Disease and Anoikis Resistance in Ewing Family of Tumors and Osteosarcoma. ONCOLOGIST , 15 (6) 627 - 635. 10.1634/theoncologist.2010-0093.

T

Taylor, RM; Franck, LS; Dhawan, A; Gibson, F; (2010) The Stories of Young People Living With a Liver Transplant. QUAL HEALTH RES , 20 (8) 1076 - 1090. 10.1177/1049732310368405.

Taylor, RM; Wray, J; Gibson, F; (2010) Measuring quality of life in children and young people after transplantation: Methodological considerations. PEDIATR TRANSPLANT , 14 (4) 445 - 458. 10.1111/j.1399-3046.2010.01316.x.

Theodoraki, A; Khoo, B; Hamda, A; Grillo, F; Meyer, T; Bouloux, PM; (2010) Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. Endocr.Pract. 1 - 12. 10.4158/EP10109.CR.

Thirlwell, C; Eymard, M; Meyer, T; Davidson, B; Teschendorff, A; Beck, S; Caplin, M; (2010) Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors Identifies Distinct Methylation Profiles and Differentially Methylated Gene Promoter Regions Associated with Low, Medium and High Grade Tumors. In: NEUROENDOCRINOLOGY. (pp. 14 - 14). KARGER

Tobias, J; Hochhauser, D; (2010) Cancer and Its Management. Wiley-Blackwell

Tolner, B; Vigor, K; Mather, S; Robinson, M; Adams, G; Plueckthun, A; Chester, K; (2010) Anti-HER2 imaging agents for breast cancer imaging. In: BREAST CANCER RESEARCH. (pp. S13 - S13). BIOMED CENTRAL LTD

Tsochatzis, E; Garcovich, M; Marelli, L; Fede, G; Germani, G; Manousou, P; ... Burroughs, AK; + view all (2010) TRANSARTERIAL CHEMOEMBOLIZATION AS NEO-ADJUVANT THERAPY PRE-TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. In: HEPATOLOGY. (pp. 858A - 859A). WILEY-BLACKWELL

Tsochatzis, E; Meyer, T; Marelli, L; Burroughs, AK; (2010) Which transarterial therapy is best for hepatocellular carcinoma? - The evidence to date. J HEPATOL , 53 (3) 588 - 588.

Turner, NC; Strauss, SJ; Sarker, D; Gillmore, R; Kirkwood, A; Hackshaw, A; ... Meyer, T; + view all (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. BRIT J CANCER , 102 (7) 1106 - 1112. 10.1038/sj.bjc.6605618.

U

Uno, JK; Rao, KN; Matsuoka, K; Sheikh, SZ; Kobayashi, T; Li, F; ... Plevy, SE; + view all (2010) Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology , 139 (5) 1642 - 1653.e6. 10.1053/j.gastro.2010.07.008.

V

Valle, J; Wasan, H; Palmer, DH; Cunningham, D; Anthoney, A; Maraveyas, A; ... ABC-02 Trial Investigators,; + view all (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. NEW ENGL J MED , 362 (14) 1273 - 1281.

Vanhaesebroeck, B; Guillermet-Guibert, J; Graupera, M; Bilanges, B; (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol , 11 (5) 329 - 341. 10.1038/nrm2882.

Vanhaesebroeck, B; Vogt, PK; Rommel, C; (2010) PI3K: From the bench to the clinic and back. Current Topics in Microbiology and Immunology , 347 (1) 1 - 19. 10.1007/82-2010-65.

Vanhaesebroeck, B; Vogt, PK; Rommel, C; (2010) PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol , 347 1 - 19. 10.1007/82_2010_65.

Vassileva, V; (2010) Screening: IL-12 polymorphism linked to cervical cancer risk. Nature Reviews Clinical Oncology , 7 (1) 6 - 6. 10.1038/nrclinonc.2009.194.

Vassileva, V; (2010) SRAP-new prognostic marker. Nature Reviews Clinical Oncology , 7 (1) 4 - 4. 10.1038/nrclinonc.2009.195.

Vassileva, V; (2010) Targeted therapies: Farletuzumab-promising new agent in ovarian cancer. Nature Reviews Clinical Oncology , 7 (1) 5 - 5. 10.1038/nrclinonc.2009.200.

Vassileva, V; Piquette-Miller, M; (2010) Inflammation: Extinguishing the Fires Within. CLIN PHARMACOL THER , 87 (4) 375 - 379. 10.1038/clpt.2010.10.

Vigor, KL; Kyrtatos, PG; Minogue, S; Al-Jamal, KT; Kogelberg, H; Tolner, B; ... Chester, KA; + view all (2010) Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. BIOMATERIALS , 31 (6) 1307 - 1315. 10.1016/j.biomaterials.2009.10.036.

W

Whelan, JS; Casali, P; Blay, JS; (2010) Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Ann Oncol , Suppl 5 198 - 203.

Whelan, JS; Casali, PG; Blay, JY; (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Ann Oncol , Suppl 5 98 - 102.

Whelan, JS; Grimer, R; Athansou, N; Gerrand, C; Judson, I; Lewis, I; ... Seddon, B; + view all (2010) UK guidelines for the management of bone sarcomas. Sarcoma 2010:317462. Epub

Whelan, JS; Hogendoorn, PC; Athanasou, N; Bielack, S; De Alava, E; Tos, AP; ... Vanel, D; + view all (2010) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol , Suppl 5 204 - 213.

Whelan, JS; Ladenstein, R; Potschger, U; Le Deley, M-C; Paulussen, M; Oberlin, O; ... Jurgens, H; + view all (2010) Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol , 10 (28) 3284 - 3291.

Y

Yap, TA; Vidal, L; Adam, J; Stephens, P; Spicer, J; Shaw, H; ... Plummer, R; + view all (2010) Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. J CLIN ONCOL , 28 (25) 3965 - 3972. 10.1200/JCO.2009.26.7278.

Yong, M; Begent, R; (2010) Best use of experimental data in cancer informatics. Future Oncol , 6 (10) 1551 - 1562. 10.2217/fon.10.108.

This list was generated on Sun Aug 17 03:24:13 2014 BST.